0G99 Stock Overview
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Oxurion NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0001 |
| 52 Week High | €0.0059 |
| 52 Week Low | €0.0001 |
| Beta | 0.51 |
| 1 Month Change | 0% |
| 3 Month Change | -75.00% |
| 1 Year Change | -98.11% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0G99 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.8% | 2.0% |
| 1Y | -98.1% | -23.3% | 4.5% |
Return vs Industry: 0G99 underperformed the UK Biotechs industry which returned -26.7% over the past year.
Return vs Market: 0G99 underperformed the UK Market which returned 3% over the past year.
Price Volatility
| 0G99 volatility | |
|---|---|
| 0G99 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0G99's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0G99's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 20 | Pascal Ghoson | www.oxurion.com |
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME.
Oxurion NV Fundamentals Summary
| 0G99 fundamental statistics | |
|---|---|
| Market cap | €1.15m |
| Earnings (TTM) | -€18.97m |
| Revenue (TTM) | €263.00k |
4.4x
P/S Ratio-0.1x
P/E RatioIs 0G99 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0G99 income statement (TTM) | |
|---|---|
| Revenue | €263.00k |
| Cost of Revenue | €159.00k |
| Gross Profit | €104.00k |
| Other Expenses | €19.07m |
| Earnings | -€18.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0033 |
| Gross Margin | 39.54% |
| Net Profit Margin | -7,212.55% |
| Debt/Equity Ratio | -91.1% |
How did 0G99 perform over the long term?
See historical performance and comparison